Literature DB >> 9733821

Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines.

B R Gundlach1, S Reiprich, S Sopper, R E Means, U Dittmer, K Mätz-Rensing, C Stahl-Hennig, K Uberla.   

Abstract

Live attenuated simian immunodeficiency viruses (SIV), such as nef deletion mutants, are the most effective vaccines tested in the SIV-macaque model so far. To modulate the antiviral immune response induced by live attenuated SIV vaccines, we had previously infected rhesus monkeys with a nef deletion mutant of SIV expressing interleukin 2 (SIV-IL2) (B. R. Gundlach, H. Linhart, U. Dittmer, S. Sopper, S. Reiprich, D. Fuchs, B. Fleckenstein, G. Hunsmann, S. Stahl-Hennig, and K. Uberla, J. Virol. 71:2225-2232, 1997). In the present study, SIV-IL2-infected macaques and macaques infected with the nef deletion mutant SIVDeltaNU were challenged with pathogenic SIV 9 to 11 months postvaccination. In contrast to the results with naive control monkeys, no challenge virus could be isolated from the SIV-IL2- and SIVDeltaNU-infected macaques. However, challenge virus sequences could be detected by nested PCR in some of the vaccinated macaques. To determine the role of immune responses directed against Env of SIV, four vaccinated macaques were rechallenged with an SIV-murine leukemia virus (MLV) hybrid in which the env gene of SIV had been functionally replaced by the env gene of amphotropic MLV. All vaccinated macaques were protected from productive infection with the SIV-MLV hybrid in the absence of measurable neutralizing antibodies, while two naive control monkeys were readily infected. Since the SIV-MLV hybrid uses the MLV Env receptor Pit2 and not CD4 and a coreceptor for virus entry, chemokine inhibition and receptor interference phenomena were not involved in protection. These results indicate that the protective responses induced by live attenuated SIV vaccines can be independent of host immune reactions directed against Env.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733821      PMCID: PMC110103     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Importance of the nef gene for maintenance of high virus loads and for development of AIDS.

Authors:  H W Kestler; D J Ringler; K Mori; D L Panicali; P K Sehgal; M D Daniel; R C Desrosiers
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

2.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Experimental infection of macaques with HIV-2ben, a novel HIV-2 isolate.

Authors:  C Stahl-Hennig; O Herchenröder; S Nick; M Evers; M Stille-Siegener; K D Jentsch; F Kirchhoff; T Tolle; T J Gatesman; W Lüke
Journal:  AIDS       Date:  1990-07       Impact factor: 4.177

4.  A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

Authors:  B L Lohman; M B McChesney; C J Miller; E McGowan; S M Joye; K K Van Rompay; E Reay; L Antipa; N C Pedersen; M L Marthas
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

5.  A formalin-inactivated whole SIV vaccine confers protection in macaques.

Authors:  M Murphey-Corb; L N Martin; B Davison-Fairburn; R C Montelaro; M Miller; M West; S Ohkawa; G B Baskin; J Y Zhang; S D Putney
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

6.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

7.  Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus.

Authors:  S M Lang; M Weeger; C Stahl-Hennig; C Coulibaly; G Hunsmann; J Müller; H Müller-Hermelink; D Fuchs; H Wachter; M M Daniel
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

8.  Immunization with tween-ether-treated SIV adsorbed onto aluminum hydroxide protects monkeys against experimental SIV infection.

Authors:  C Stahl-Hennig; G Voss; S Nick; H Petry; D Fuchs; H Wachter; C Coulibaly; W Lüke; G Hunsmann
Journal:  Virology       Date:  1992-02       Impact factor: 3.616

9.  Insufficient inactivation of HIV-1 in human cryo poor plasma by beta-propiolactone: results from a highly accurate virus detection method.

Authors:  S G Norley; J Löwer; R Kurth
Journal:  Biologicals       Date:  1993-09       Impact factor: 1.856

10.  Early phenotypic and functional alterations in lymphocytes from simian immunodeficiency virus infected macaques.

Authors:  C Kneitz; T Kerkau; J Müller; C Coulibaly; C Stahl-Hennig; G Hunsmann; T Hünig; A Schimpl
Journal:  Vet Immunol Immunopathol       Date:  1993-04       Impact factor: 2.046

View more
  11 in total

1.  Quintuple deglycosylation mutant of simian immunodeficiency virus SIVmac239 in rhesus macaques: robust primary replication, tightly contained chronic infection, and elicitation of potent immunity against the parental wild-type strain.

Authors:  K Mori; Y Yasutomi; S Ohgimoto; T Nakasone; S Takamura; T Shioda; Y Nagai
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef.

Authors:  E Khatissian; V Monceaux; M C Cumont; M P Kieny; A M Aubertin; B Hurtrel
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Genotyping and segregation analyses indicate the presence of only two functional MIC genes in rhesus macaques.

Authors:  Anne Averdam; Sandra Seelke; Immanuel Grützner; Cornelia Rosner; Christian Roos; Nico Westphal; Christiane Stahl-Hennig; Vijayakumar Muppala; Annette Schrod; Ulrike Sauermann; Ralf Dressel; Lutz Walter
Journal:  Immunogenetics       Date:  2007-01-11       Impact factor: 2.846

Review 5.  Efficacy of AIDS vaccine strategies in nonhuman primates.

Authors:  Klaus Uberla
Journal:  Med Microbiol Immunol       Date:  2005-04-21       Impact factor: 3.402

6.  Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain.

Authors:  B R Gundlach; M G Lewis; S Sopper; T Schnell; J Sodroski; C Stahl-Hennig; K Uberla
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

7.  The Role of CD4(+) and CD8(+) T Cells in Controlling HIV Infection.

Authors:  Stephen A. Migueles; Mark Connors
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

8.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

9.  Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus.

Authors:  Simone Giannecchini; Mauro Pistello; Patrizia Isola; Donatella Matteucci; Paola Mazzetti; Giulia Freer; Mauro Bendinelli
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

10.  Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.

Authors:  K J Metzner; X Jin; F V Lee; A Gettie; D E Bauer; M Di Mascio; A S Perelson; P A Marx; D D Ho; L G Kostrikis; R I Connor
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.